Clinical Trials
4 trialsNCT00071981 2023-06-28
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00706992 2015-10-28
Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00003222 2014-12-19
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
University of Virginia
Phase 2 Completed
NCT00001703 2014-07-25
Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated